SALT LAKE CITY, April 24, 2018 -- Nu-Med Plus, Inc. (OTCBB:NUMD), a medical device development company, announced that on April 10, 2018, shareholders voted to re-elect all the existing highly qualified directors, Jeffrey Robins, William Moon, Thomas Tait, Dr. Craig Morrison and Dr. Brett J. Earl, to the Nu-Med Plus Board of Directors.
Sadler, Gibb and Associates LLC was also reaffirmed to serve as Nu-Med's independent registered public accounting firm and auditor.
Jeff Robins, Chairman of the Board and CEO of Nu-Med Plus, Inc., remarked, "I greatly appreciate the strong support from our shareholders and the reaffirmation of their confidence in the Board and our management team by re-electing all 5 of our incumbent directors. This strong vote of confidence recognizes their hard work and relentless focus since the inception of our company. We are more energized than ever about building on Nu-Med's strengths to anticipate and deliver our INO products to the medical community. We plan to maintain an active and productive dialogue with shareholders as we continue to transform our business and create value for all of our stakeholders."
About Nu-Med Plus, Inc.
Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed Nitric Oxide technologies. The emphasis is to generate controlled-flow of INO for internal therapies with integrating accessories for availability in hospitals, emergency rooms and urgent care facilities, medical and chiropractic offices, convalescent and nursing homes, and for emergency response teams for treatment of various trauma injuries. For more company information please visit www.nu-medplus.com.
Contact: Keith Merrell/CFO (801) 746 3570
Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.


Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems
How Marco Pharma International Preserves German Homeopathic Traditions in America
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks
Vietnam Approves SpaceX Starlink Satellite Internet Service Amid U.S. Trade Talks
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 



